Comment from National Tay-Sachs & Allied Diseases Association, Inc.

The patient stories shared through NTSAD’s Patient-Focused Drug Development Meeting on GM2 (Tay-Sachs and Sandhoff diseases) in 2024—as well as those shared in the subsequent Listening Session on infantile/juvenile GM1 and GM2 (2025), a past Listening Session on Late Onset GM2 (2021), and a Listening Session on Canavan disease (2023)—have helped shape conversations well beyond those forums. By capturing the lived experiences of individuals and families affected by Tay-Sachs, Sandhoff, GM1 gangliosidosis, and Canavan disease, these efforts have deepened community engagement and encouraged more families to share their own journeys. This growing openness has strengthened connections across the rare disease community and elevated awareness of the daily realities, unmet needs, and challenges families face - and perhaps most importantly, shed light on the urgent need for approved therapies. While the impact is not easily quantified, these narratives have informed advocacy strategies and helped ensure that the voices of patients and caregivers remain central in discussions with researchers, clinicians, and other stakeholders. These insights have also contributed to more informed dialogue with NTSAD's industry partners, particularly around clinical trial design. Patient and caregiver perspectives—on topics such as meaningful endpoints, quality of life considerations, and participation barriers like placebo-controlled trial requirements—offer critical context that may not emerge through traditional clinical or regulatory channels. By sharing these experiences, NTSAD aims to encourage the development of trials that are more responsive to patient needs and realities. At the same time, the stories have inspired broader participation in advocacy efforts, reinforcing the idea that lived experience is a powerful driver of awareness, collaboration, and progress toward effective therapies.